Advanced Filters
noise

transplant-rejection Clinical Trials

A listing of transplant-rejection medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 48 clinical trials
K Kitza Williams, MSN, FNP

Treatment of Antibody-Mediated Rejection (ABMR) With CarBel

The purpose of this study is to see: If using these two drugs (carfilzomib and belatacept) together is safe If the use of these two study drugs in addition to the usual immunosuppression for kidney transplant patients can improve your transplanted kidney function by lowering the antibodies you have against …

18 - 75 years of age All Phase 2
A Alberto Benazzo, MD

A Prospective Randomized Trial of ECP in Subclinical AMR

The goal of this clinical trial is to evaluate the therapeutic effect of extracorporeal photopheresis in subclinical antibody-mediated rejection after lung transplantation.The main questions it aims to answer are: Does ECP therapy result in a significant reduction in MFI (Mean Fluorescence Intensity) from the baseline MFI in clinically stable patients …

18 years of age All Phase N/A
D David Gomez de Antonio, PhD

Safety of Endobronchial Mesenchymal Stromal Cells in the Treatment of Chronic Lung Allograft Dysfunction

Lung transplantation is the only therapeutic alternative for more and more patients with respiratory diseases in their most advanced stages. The most limiting factor to achieve long term survival si chronic lung allograft dysfunction, a multifactorial disease without an effective treatment. The immunomodulatory capacity of mesenchymal stem cells enables them …

18 years of age All Phase 1
J Jenny Lester

Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor

The purpose of this study is to find out if an investigational treatment will allow kidney transplant recipients to better accept their new kidney and stop immunosuppressive medicines. This study is for kidney transplant recipients who receive a kidney from a sibling donor. The investigational treatment is started after kidney …

18 years of age All Phase 1/2
O Olena Ashworth

Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients

We will conduct a two-group randomized controlled trial to examine the eMocha DOT intervention with pediatric HT recipients.In this population, medication nonadherence remains a primary cause of late acute rejection (LAR) episodes, increased number of hospitalizations, graft failure, and patient mortality. Herein, we propose an innovative approach to promote medication …

10 - 21 years of age All Phase N/A
C Charline Vauchy, PhD

MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy

The objective of this study is to describe the type of cell death induced by extracorporeal photochemotherapy, depending on the cell type, using a panel of complementary analysis techniques.

18 - 85 years of age All Phase N/A
H Huan Yang, Phd

CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

This clinical trial investigates the transplantation of donor kidneys that have been genetically modified ex vivo using CRISPR-Cas9 genome editing to reduce immunogenicity and transplant rejection. Donor kidney grafts will have key human leukocyte antigen (HLA) genes disrupted - specifically, knockout of HLA class I heavy chains HLA-A and HLA-B, …

16 - 85 years of age All Phase 1/2
F Francesc Moreso, MD, PhD

Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure

The goal of this clinical trial is to compare the degree of HLA sensitization at 2 years in patients with late renal graft failure (> 3 months) when receiving reduced immunosuppressant treatment versus stopping immunosuppression at 6 months. The main question this study aims to answer is: Does maintaining long-term …

18 years of age All Phase 4
H Huan Yang, Phd

CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection

This early-phase clinical trial will assess the use of ex vivo CRISPR-Cas9 genome editing on donor liver grafts to reduce immunogenicity before transplantation. Donor livers will have HLA-A and HLA-B genes knocked out, and HLA class II expression disabled (by targeting the CIITA transactivator gene), aiming to create a "hypoimmunogenic" …

16 - 85 years of age All Phase 1/2
D Daniel Kreisel, MD, PhD

Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation

Objective: To evaluate the potential impact of molecular phenotyping of transbronchial biopsies in lung transplant recipients with allograft dysfunction, and the potential for developing a safer endobronchial mucosal biopsy format.

18 years of age All Phase N/A

Simplify language using AI